摘要
Abstract
Objective:To explore the effects of pemetrexed combined with cisplatin on inflammatory factors,tumor markers and immune function in patients with non-small cell lung cancer(NSCLC).Methods:A total of 100 NSCLC patients admitted to a hospital from January 2021 to August 2024 were retrospective selected and divided into the control group(n=50)and the study group(n=50)according to treatment methods.The control group was treated with docetaxel injection combined with cisplatin injection,while the study group was treated with pemetrexed disodium for injection combined with cisplatin injection.Clinical efficacy,tumor markers[carcinoembryonic antigen(CEA),neuron-specific enolase(NSE),carbohydrate antigen 125(CA125),cytokeratin 19 fragment antigen 21-1(CYFRA21-1),cytokeratin 19(CK19)],immune function indicators(CD4+,CD8+,CD3+,CD4+/CD8+),inflammatory factors[procalcitonin(PCT),interleukin-6(IL-6),C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)]and adverse reactions were compared between the two groups.Results:After treatment,the total effective rate in the study group(62.00%)was higher than that in the control group(32.00%,P<0.05).Levels of CEA,NSE,CA125,CYFRA21-1,CK19,PCT,IL-6,CRP and TNF-α were decreased in both groups,with lower levels in the study group(P<0.05).CD4+,CD3+and CD4+/CD8+were increased in both groups,with higher levels in the study group(P<0.05).Repeated measures analysis showed statistically significant differences in time points,between groups and interaction effects of CEA,CA125,CYFRA21-1,CK19,CD3+,CD4+/CD8+,PCT,IL-6,CRP and TNF-α between the two groups(P<0.05).The total incidence of adverse reactions in the study group(44.00%)was lower than that in the control group(64.00%,P<0.05).Conclusion:Pemetrexed combined with cisplatin chemotherapy can effectively control tumor progression in NSCLC patients,reduce inflammatory factors and tumor marker levels,improve immune function.关键词
培美曲塞/顺铂/非小细胞肺癌/炎症因子/肿瘤标志物/免疫功能Key words
pemetrexed/cisplatin/non-small cell lung cancer/inflammatory factor/tumor marker/immune function分类
医药卫生
